Hans Ulrichts

Hans Ulrichts is the current Chief Development Officer at Aelin Therapeutics. Prior to this, they served as the Director of Bioanalytical Scientific Management at UCB from June 2017 to October 2021. In this role, they managed an international team of 8 PhDs and was responsible for the development and execution of a bioanalytical strategy for NBE and NCE programs. Ulrichts has also held the position of Head Pharmacology at Ablynx from January 2006 to May 2017. Hans began their career as a post-doctoral researcher at the Royal College of Surgeons in Ireland in Dublin, Ireland from February 2006 to July 2006. Hans then moved to the Laboratory for Thrombosis Research at Catholic University of Leuven in Belgium, where they worked from October 2003 to December 2005.

Hans Ulrichts was educated as a biochemist, obtaining their PhD from KU Leuven. Hans also holds a Licentiaat from KU Leuven in the same field, as well as a Kandidaat in Chemistry from the same school.

Some of their coworkers include Paul Vauterin - Chief Information Officer, Andreas Rybka - Head of Chemistry, and Noor Remmerie - Program Manager. Hans Ulrichts reports to Els Beirnaert, CEO.